42 patents
Utility
Process For Preparing Aminopyrimidine Derivatives
5 Oct 23
The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors.
Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
Filed: 2 Jun 23
Utility
Pharmaceutical Compositions Comprising a Diaminopyrimidine Derivative or Pharmaceutically Acceptable Salt Thereof and Processes for Preparing the Same
17 Aug 23
The present invention provides a pharmaceutical composition comprising (S)—N-(1-(2-((4-amino-3-nitrophenyl)amino)-6-propylpyrimidin-4-yl)pyrrolidin-3-yl)acetamide or a pharmaceutically acceptable salt thereof having an activity as a 5-HT4 receptor agonist and an acidifying agent; and a process for preparing the same.
Dong-Min Park, Su-Hyeon Kim, Eun-Pa Cheon, Tae-Lin Ha, Jun-Mo Yang, Yoong-Sik Park
Filed: 1 Jul 21
Utility
Method for Producing Dual Function Proteins and Its Derivatives
6 Jul 23
A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein.
Byung Hyun CHOI, In Hwan LIM, Jun Young PARK, Jin Hyoung LEE, Ki Hong KIM, Hae Yong JO, Jun Hwan KIM, Moo Young SONG, Jong Gyun KIM
Filed: 19 Dec 22
Utility
5-MEMBERED Heteroaryl-containing Aminopyridine Compounds As Egfr Inhibitors
23 Mar 23
Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
Filed: 26 Aug 22
Utility
Substituted Aminopyridine Compounds As Egfr Inhibitors
23 Mar 23
Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Hyunjoo LEE, Su Bin CHOI, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell Robertson, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
Filed: 26 Aug 22
Utility
6-MEMBERED Heteroaryl-containing Aminopyridine Compounds As Egfr Inhibitors
23 Mar 23
Provided are 6-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Hyunjoo LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM
Filed: 26 Aug 22
Utility
Substituted Aminopyridine Compounds As Egfr Inhibitors
23 Mar 23
Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Sol PARK, Heejun KIM, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Tae Kyun KIM, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON
Filed: 26 Aug 22
Utility
3,3-DIFLUOROALLYLAMINES or Salts Thereof and Pharmaceutical Compositions Comprising the Same
9 Feb 23
The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Eui Chul LEE, Sol PARK, Hyok Jun CHO, Cheol Hee LIM, So Young KIM, Hyun Ho CHOI, Da Na JEONG, Na Yeon YANG, Na Ry HA
Filed: 6 Jul 21
Utility
Salt of an Aminopyridine Derivative Compound, a Crystalline Form Thereof, and a Process for Preparing the Same
26 Jan 23
The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same.
Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
Filed: 17 Mar 22
Utility
Novel Derivatives Having 2,3-DIHYDRO-1H-INDENE or 2,3-DIHYDROBENZOFURAN Moiety or Pharmaceutically Acceptable Salt Thereof and Pharmaceutical Compositions Comprising the Same
5 Jan 23
Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Ji-Hye KIM
Filed: 12 Nov 20
Utility
Novel Compounds Having Inhibitory Activity Against Glucosylceramide Synthase or Pharmaceutically Acceptable Salt Thereof, Processes for Preparing the Same, and Pharmaceutical Compositions Comprising the Same
5 Jan 23
Provided are a compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON
Filed: 12 Nov 20
Utility
Long-acting GDF15 Fusion Protein and Pharmaceutical Composition Comprising Same
5 Jan 23
A fusion protein including a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition containing the same are disclosed.
Seyoung LIM, Young Bong PARK, Sukyung KIM, Bo Ra SIM, Wonee CHONG, Hyun Ho CHOI, Ji Eun YANG, Mi Kyeong JU, Won Tae KIM, Youn Woo LEE, Junhwan KIM
Filed: 25 Nov 20
Utility
Novel Derivatives Having 1,2,3,4-TETRAHYDRONAPHTHALENE Moiety or Pharmaceutically Acceptable Salt Thereof and Pharmaceutical Compositions Comprising the Same
22 Dec 22
Provided are a compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Young-Gyu KONG, Sang-Ho MA, Ick-Hwan SON
Filed: 12 Nov 20
Utility
Novel Processes for Preparing a Diaminopyrimidine Derivative or Acid Addition Salt Thereof
1 Dec 22
The present invention provides a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist.
Ja-Heouk KHOO, Doo-Byung LEE, Jun-Sup LEE, Hyun JU, Woo-Seob SHIN
Filed: 26 Jul 22
Utility
Triazolones, Tetrazolones, and Imidazolones, or Their Salts, and Pharmaceutical Compositions Comprising the Same
1 Dec 22
The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Hee Jae TAK, Eun Kyung KIM, Hyok Jun CHO, Cheol Hee LIM
Filed: 21 Apr 22
Utility
Process For Preparing Aminopyrimidine Derivatives
8 Sep 22
The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors.
Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
Filed: 25 Mar 22
Utility
Processes for Preparing (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE or a Salt Thereof and Processes for Preparing Tofacitinib Using the Same
12 May 22
Provided are a novel process for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof, which is an intermediate useful for the preparation of tofacitinib, an intermediate used in the process, i.e., isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)carbamate dibenzoyl-L-tartrate, an intermediate, having excellent stability, useful for the preparation of tofacitinib, i.e., (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate, and a process for preparing tofacitinib or a pharmaceutically acceptable salt thereof.
Sang-Ho OH, Doo-Byung LEE, Kyoung-Chan KWON, Sang-Won KIM, Hyo-Ick HWANG, Kyeong-Sill LEE, Ik-Su JO, Ji-Hye CHOI, Sung-Hee CHO, Su-Young LEE
Filed: 3 Apr 20
Utility
TRIAZOLOPYRIDIN-3-ONES or Their Salts and Pharmaceutical Compositions Comprising the Same
27 Jan 22
The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Dong Hoon KIM, Su Bin CHOI, Sol PARK, Hyun Ho CHOI, Tae Wang KIM, Mi Kyeong JU, Na Ry HA
Filed: 6 Jul 21
Utility
Long-acting FGF21 Fusion Proteins and Pharmaceutical Composition Comprising Same
6 Jan 22
A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin.
Jun Hwan KIM, Seyoung LIM, Minji SEO, Hyun Ho CHOI, Dohoon KIM, Mi Kyeong JU, Ju-Young PARK, Byung Hyun CHOI, Jun Kyung LEE, Jong Gyun KIM, Su Youn NAM
Filed: 17 Sep 21
Utility
Dual Function Proteins Comprising FGF21 Mutant Protein and Pharmaceutical Composition Comprising Same
6 Jan 22
A dual function protein is disclosed.
Jun Hwan KIM, Seyoung LIM, Minji SEO, Hyun Ho CHOI, Dohoon KIM, Mi Kyeong JU, Ju-Young PARK, Seul Gi KIM, Sangmyoun LIM, Jong Gyun KIM, Su Youn NAM
Filed: 17 Sep 21